BMRN vs CTAS · P/E 40, rev $1.76B vs P/E 51, rev $11.26B
Biomarin Pharmaceutical Inc (BMRN) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the BMRN and CTAS stock pages for the full models.
Not investment advice.